BriaCell Higher as it Reports "Standard-Beating" Survival Data From Phase 2 Study

MT Newswires
2024-10-22

BriaCell Therapeutics (BCT.TO) was last seen up 3.6% after the company on Tuesday released new positive data in its Phase 2 metastatic breast cancer (MBC) study.

In the study, patients treated with the same Bria-IMT regimen formulation being used in the ongoing Phase 3 pivotal trial experienced a one-year survival rate of 55% (i.e. 55% of patients remain alive at least one year after starting on the study). This rate exceeds the survival data of the current standard of care for similar patients. Four of the 13 patients recruited in 2022 remain in survival follow-up.

According to the statement, final median overall survival calculation for the Phase 2 study is pending, as many patients remain alive. Furthermore, no Bria-IMT related discontinuations have been reported.

"With over 40,000 deaths each year in the US alone, late-stage MBC remains an important unmet medical need for many patients and their families. Approved treatments are restricted by poor survival and harsh side effects," said Adam Brufsky, Professor of Medicine at the University of Pittsburgh School of Medicine. "We are impressed with BriaCell's promising randomized Phase 2 survival data indicating robust survival and a preferred tolerability profile for Bria-IMT and look forward to seeing the data being replicated in BriaCell's pivotal Phase 3 study."

BriaCell was last seen up $0.04 to $1.15 on the Toronto Stock Exchange.







免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10